Authors’ reply to the letter to the editor regarding 'Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes'

MLA

Domenico Tricò, and Anna Solini. “Authors’ Reply to the Letter to the Editor Regarding ‘Effect of Empagliflozin on Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Patients with Type 2 Diabetes.’” Diabetes Research and Clinical Practice, vol. 191, Sept. 2022, p. 110018. EBSCOhost, https://doi.org/10.1016/j.diabres.2022.110018.

APA

Domenico Tricò, & Anna Solini. (2022). Authors’ reply to the letter to the editor regarding “Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes.” Diabetes Research and Clinical Practice, 191, 110018. https://doi.org/10.1016/j.diabres.2022.110018

Chicago

Domenico Tricò, and Anna Solini. 2022. “Authors’ Reply to the Letter to the Editor Regarding ‘Effect of Empagliflozin on Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Patients with Type 2 Diabetes.’” Diabetes Research and Clinical Practice 191 (September): 110018. doi:10.1016/j.diabres.2022.110018.